Study of HEC53856 in Patients With Subjects With End-Stage Renal Disease Receiving Dialysis.
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT04925674
- Locations
- 🇨🇳
General Hospital of Tianjin Medical University, Tianjin, China
🇨🇳The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳Sichuan Provincial People's Hospital, Chengdu, China
HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia
- Conditions
- Interventions
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2021-06-24
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT04925661
- Locations
- 🇨🇳
The sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
🇨🇳Zhejiang Provincal People's Hospital, Hangzhou, China
🇨🇳The People's Hospital of Guangxi Zhuang Autonmous Region, Nanning, China
A Study to Evaluate the Tolerability, Safety, Pharmacokinetics of HEC89736 in Patients With Relapsed or Refractory B-cell Hematologic Malignancies
- First Posted Date
- 2021-04-29
- Last Posted Date
- 2022-05-06
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT04865458
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Jiangsu Province Hospital, Nanjing, Jiangsu, China
A Clinical Trial to Evaluate Clifutinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia(AML)
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2022-08-12
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT04827069
- Locations
- 🇨🇳
the First Affiliated Hospital,College of Medicine,Zhejiang University, Hanzhou, China
the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC83518 Tablets
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2021-05-10
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 52
- Registration Number
- NCT04667429
- Locations
- 🇨🇳
The Shanghai Xuhui Central Hospital, Shanghai, Shanghai, China
Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC122505MsOH Tablets in Healthy Adult Subjects
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 106
- Registration Number
- NCT04625361
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, China
the Safety, Tolerability, and Pharmacokinetics Study of HEC113995
- Conditions
- Interventions
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2020-11-25
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 58
- Registration Number
- NCT04623814
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, China
The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC83518 Tablets in Chinses Healthy Subjects
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2021-05-10
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT04596007
- Locations
- 🇨🇳
The Shanghai xuhui district central hospital, Shanghai, Shanghai, China
The Safety, Tolerability, and Pharmacokinetics Study of HEC113995 PA•H2O Tablets in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 69
- Registration Number
- NCT04591301
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, China
First-In-Human Phase I Trial of Ningetinib ( CT053PTSA ) in the Patients With Advanced Solid Tumors
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT04577703
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China